We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study
Read MoreHide Full Article
AstraZeneca PLC (AZN - Free Report) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab). The candidate is meant for the sequential treatment of patients with locally-advanced, unresectable (stage III) non-small cell lung cancer (NSCLC).
The PACIFIC study is a randomized, double-blinded, placebo-controlled multi-center study. It is being conducted in 235 centers across 26 countries. The study met its primary endpoints and demonstrated statistically-significant and clinically-meaningful progression free survival (PFS). Imfinzi led to significant reductions in the risk of deterioration of health or death, per data from the study. The results also demonstrate a favorable benefit/risk profile. Investors should note that Imfinzi is the first immuno-oncology medicine to show superior PFS compared to placebo in this patient setting.
Astrazeneca’s shares have significantly outperformed the Zacks classified Large Cap Pharma industry so far this year. Shares of the company have gained 24.4%, while the industry registered an increase of 8.6%.
We remind investors that earlier this month the FDA granted accelerated approval to Imfinzi for the treatment of previously treated patients with advanced bladder cancer.
Please note that Roche’s (RHHBY - Free Report) Tecentriq is also approved for bladder cancer as well as for patients unable to tolerate cisplatin-containing chemo.
Per the company’s press release, stage III lung cancer affected around 100,000 patients in the G7 countries in 2016. Among them about 50% of these patients have tumors that are unresectable. Thus, approval of Imfinzi will provide the company access to a huge population base of patients affected by the disease.
We note that Imfinzi is being evaluated as a monotherapy as well as a combination treatment across a wide range of cancers including head and neck, gastric, pancreatic, hepatocellular and blood cancers.
Among other large cap pharma companies, Bristol-Myers Squibb Company’s (BMY - Free Report) Opdivo and Merck & Co., Inc.’s (MRK - Free Report) Keytruda are also approved for immuno-oncology treatments.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study
AstraZeneca PLC (AZN - Free Report) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab). The candidate is meant for the sequential treatment of patients with locally-advanced, unresectable (stage III) non-small cell lung cancer (NSCLC).
The PACIFIC study is a randomized, double-blinded, placebo-controlled multi-center study. It is being conducted in 235 centers across 26 countries. The study met its primary endpoints and demonstrated statistically-significant and clinically-meaningful progression free survival (PFS). Imfinzi led to significant reductions in the risk of deterioration of health or death, per data from the study. The results also demonstrate a favorable benefit/risk profile. Investors should note that Imfinzi is the first immuno-oncology medicine to show superior PFS compared to placebo in this patient setting.
Astrazeneca’s shares have significantly outperformed the Zacks classified Large Cap Pharma industry so far this year. Shares of the company have gained 24.4%, while the industry registered an increase of 8.6%.
We remind investors that earlier this month the FDA granted accelerated approval to Imfinzi for the treatment of previously treated patients with advanced bladder cancer.
Please note that Roche’s (RHHBY - Free Report) Tecentriq is also approved for bladder cancer as well as for patients unable to tolerate cisplatin-containing chemo.
Per the company’s press release, stage III lung cancer affected around 100,000 patients in the G7 countries in 2016. Among them about 50% of these patients have tumors that are unresectable. Thus, approval of Imfinzi will provide the company access to a huge population base of patients affected by the disease.
We note that Imfinzi is being evaluated as a monotherapy as well as a combination treatment across a wide range of cancers including head and neck, gastric, pancreatic, hepatocellular and blood cancers.
Among other large cap pharma companies, Bristol-Myers Squibb Company’s (BMY - Free Report) Opdivo and Merck & Co., Inc.’s (MRK - Free Report) Keytruda are also approved for immuno-oncology treatments.
Astrazeneca PLC Price
Astrazeneca PLC Price | Astrazeneca PLC Quote
Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>